<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590925</url>
  </required_header>
  <id_info>
    <org_study_id>4-2018-0075</org_study_id>
    <nct_id>NCT03590925</nct_id>
  </id_info>
  <brief_title>Evaluation of the Improvement of Primary Prevention in Ischemic Cardiomyopathy Patients Using New Screening and Referring System (Advance-ICM)</brief_title>
  <official_title>Evaluation of the Improvement of Primary Prevention in Ischemic Cardiomyopathy Patients Using New Screening and Referring System (Advance-ICM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients who undergo ICD(implantable cardioverter defibrillator) implantation for the
      primary prevention of sudden cardiac death with severe LV(left ventricle) dysfunction
      (ejection fraction ≤ 40%) by ICM(idiopathic cardiomyopathy).

      Indications for ICD implantation for primary prevention in accordance with 2016 revised
      Korean indication guideline on ICD implantation

        -  FU LVEF(Left Ventricular Ejection Fraction) ≤ 30% (at least 40 days post-myocardial
           infarction)

        -  FU LVEF 31~35%, NYHA(the New York Heart Association) class II, III (at least 40 days
           post-myocardial infarction)

        -  FU LVEF ≤ 40%, NSVT(non-sustained ventricular tachycardia) (Holter), inducible
           VF(ventricular flutter) or sustained VT(ventricular tachycardia) at electrophysiological
           study (at least 40 days post-myocardial infarction)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of the quality of care in patients with ICM</measure>
    <time_frame>3 years</time_frame>
    <description>the rate of device therapy(ICD or CRT-D(Cardiac Resynchronization Therapy-Device))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of the cardiovascular outcome of patients</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiovascular outcome (cardiovascular death, Non-cardiovascular death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the cardiovascular outcome of patients</measure>
    <time_frame>3 years</time_frame>
    <description>Pattern of arrhythmia measured by EKG or echocardiography</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>new screening and referring system of ICD</arm_group_label>
    <description>Non-randomized, non-blinded, multi-center study receiving new screening and referring system of ICD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patients who undergo ICD implantation for the primary prevention of sudden cardiac
        death with severe LV dysfunction (ejection fraction ≤ 40%) by ICM.

        Indications for ICD implantation for primary prevention in accordance with 2016 revised
        Korean indication guideline on ICD implantation

          -  FU LVEF ≤ 30% (at least 40 days post-myocardial infarction)

          -  FU LVEF 31~35%, NYHA class II, III (at least 40 days post-myocardial infarction)

          -  FU LVEF ≤ 40%, NSVT (Holter), inducible VF or sustained VT at electrophysiological
             study (at least 40 days post-myocardial infarction)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years

          -  Patients eligible for the indications for ICD implantation for primary prevention
             indication in accordance with 2016 revised Korean indication guideline on ICD
             implantation

          -  Patients should be managed by non-EP physician

          -  Patients who are willing to sign the informed consent

          -  Patients who are willing to receive the implantation and post-operative follow-up

        Exclusion Criteria:

          -  Malignant tumor

          -  Life expectancy &lt; 12 months

          -  Patients unable or unwilling to cooperate in the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Yonsei University Health System, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boyoung Joung, MD, Ph.D</last_name>
      <phone>82-2-2228-8460</phone>
      <email>cby6908@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

